Free Market Evaluation - Send us your resume and we will give you free feedback
Charter Merges with Time Warner Cable
Charter Merges with Time Warner Cable
Criminal Charges for ConAgra Foods
Criminal Charges for ConAgra Foods
American Apparel Hit with Another Lawsuit from Former CEO
American Apparel Hit with Another Lawsuit from Former CEO
Uber Made Legal in the Philippines
Uber Made Legal in the Philippines
Legal Job Listings
Download PDF

Roche Doubles Alzheimer’s Test Group View Count: 48

A Swiss drug manufacturer, Roche Holding AG, feels that it has taken the lead in the race to develop a drug that could alter the course of Alzheimer’s disease since many other companies suffered setbacks.  A clinical trial operated by the company has been doubled in size so its experimental drug known as gantenerumab can be tested in patients who have not been diagnosed with dementia yet.

“The playing field has changed dramatically and gantenerumab is now the most advanced monoclonal antibody in early Alzheimer’s and the next big news to read out in this space,” Luca Santarelli, Roche’s head of neuroscience, said in an interview with Yahoo News.

“We targeted this space four years ago and our trial started at the end of 2010, so we are way ahead,” Santarelli said.

Get JD Journal in Your Mail
Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!




The data from the study is not expected to be released until sometime in 2015. The trial, which has increased from 360 patients to 770 patients moves it into a final-stage Phase III. Roche hopes that the trial will show an effect because tests have shown that the drug being tested can help reduce amyloid plaques in the brain. These plaques are linked to the disease.

Roche might be able to file for marketing approval with just one trial if the company’s results are incredibly strong. There are three other drugs being tested by Roche right now and they include crenezumab. This drug was picked by the U.S. government for a trial in Colombians who suffer from genetic mutations that cause Alzheimer’s in their 40s.

Roche Doubles Alzheimer's Test Group by

Tagged: , , , ,

Posted by on September 7, 2012. Filed under Business News. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.

 

 

Job of the Day
Banking/Finance Associate
USA-NY-New York City
Sophisticated midsize firm located in NYC seeks an associate with 3+ years of experience in banking transactions representing financial institutions and banks in syndicated financings. ...


Apply now

Related Posts: